Jacob L van Dam

13PUBLICATIONS
72CO-AUTHORS
Oncology and carcinogenesis not elsewhere classifiedPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Oct 22, 2026
Survival impact of involvement of lymph node stations 16b1, 9, and 8a during pancreatoduodenectomy for pancreatic and periampullary cancers (PANODE): prospective multicentre study.

|Jan 29, 2026
Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial.

Ruth A L Willems, Aniek E van Diepen, Esther N Dekker

|May 06, 2025
Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an international multicentre study.

Thomas F Stoop, Y H Andrew Wu, Atsushi Oba

|Feb 05, 2024
Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study.

Esther N Dekker, Jacob L van Dam, Quisette P Janssen

|Jul 13, 2023
Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials.

Deesje Doppenberg, Jacob L van Dam, Youngmin Han

|Jul 18, 2022
Treatment Response and Conditional Survival in Advanced Pancreatic Cancer Patients Treated with FOLFIRINOX: A Multicenter Cohort Study.

Fleur van der Sijde, Jacob L van Dam, Bas Groot Koerkamp

Pageof 3

Frequent Collaborators

10 joint publications

Bas Groot Koerkamp

9 joint publications

Marc G Besselink

5 joint publications

Olivier R Busch

4 joint publications

Judith de Vos-Geelen